Your browser doesn't support javascript.
loading
Molecular-genetic diagnostics of von Hippel-Lindau syndrome (VHL) in Bulgaria: first complex mutation event in the VHL gene.
Glushkova, Maria; Dimova, Petia; Yordanova, Iglika; Todorov, Tihomir; Tourtourikov, Ivan; Mitev, Vanyo; Todorova, Albena.
Affiliation
  • Glushkova M; a Department of Medical Chemistry and Biochemistry , Medical University Sofia , Sofia , Bulgaria.
  • Dimova P; c Genetic Medico-Diagnostic Laboratory Genica , Sofia , Bulgaria.
  • Yordanova I; b Epilepsy Center, Department of Neurosurgery , University Hospital 'St. Ivan Rilski' , Sofia , Bulgaria.
  • Todorov T; c Genetic Medico-Diagnostic Laboratory Genica , Sofia , Bulgaria.
  • Tourtourikov I; c Genetic Medico-Diagnostic Laboratory Genica , Sofia , Bulgaria.
  • Mitev V; c Genetic Medico-Diagnostic Laboratory Genica , Sofia , Bulgaria.
  • Todorova A; a Department of Medical Chemistry and Biochemistry , Medical University Sofia , Sofia , Bulgaria.
Int J Neurosci ; 128(2): 117-124, 2018 Feb.
Article in En | MEDLINE | ID: mdl-28849724
ABSTRACT
Von Hippel-Lindau syndrome is an autosomal-dominant disease characterized by the formation of various tumours and cysts in many different parts of the body. Von Hippel-Lindau syndrome is caused by VHL gene mutations leading to production of impaired tumor suppressor Von Hippel-Lindau syndrome protein or its complete absence.

PURPOSE:

To study five patients with clinically suspected Von Hippel-Lindau syndrome, who were referred for molecular genetic testing.

METHODS:

Sanger sequencing of the coding regions of the VHL gene.

RESULTS:

Five clinically relevant germline mutations were detected. One of the pathogenic variants has not been previously reported. This novel mutation is a complex mutation event combining a duplication and an indel, rearranging exon 3 of the VHL gene - c. [516_517dupGTCAAGCCT; 532_542delCTGGACATCGTinsATTA], p. (Glu173Serfs*4).

CONCLUSION:

Overall, our results showed that the diagnosis of Von Hippel-Lindau syndrome in our country is difficult most probably because of its heterogeneous clinical manifestation and insufficient knowledge on the diagnostic criteria for the disease. From genetic point of view our results add some novel data on the mutation profile of the VHL gene. In order to prove or revise the diagnosis, early genetic testing is strongly recommended in affected patients and their family members to ensure appropriate follow-up and treatment of the malignancies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Von Hippel-Lindau Tumor Suppressor Protein / Von Hippel-Lindau Disease Type of study: Diagnostic_studies / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Int J Neurosci Year: 2018 Document type: Article Affiliation country: Bulgaria

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Von Hippel-Lindau Tumor Suppressor Protein / Von Hippel-Lindau Disease Type of study: Diagnostic_studies / Prognostic_studies Limits: Adolescent / Adult / Female / Humans / Middle aged Country/Region as subject: Europa Language: En Journal: Int J Neurosci Year: 2018 Document type: Article Affiliation country: Bulgaria